EKSO BIONICS HOLDINGS INC (EKSO) Stock Price, Quote, News and Overview
NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD
EKSO Quote, Performance and Key Statistics
3.8
+0.07 (+1.88%)
The current stock price of EKSO is 3.8 USD. In the past month the price increased by 5.85%. In the past year, price decreased by -79.23%.
EKSO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.24 | 215.17B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.88 | 185.88B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.39 | 153.33B | ||
| SYK | STRYKER CORP | 31.08 | 148.81B | ||
| MDT | MEDTRONIC PLC | 16.29 | 114.81B | ||
| BDX | BECTON DICKINSON AND CO | 12.69 | 51.26B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.42 | 44.87B | ||
| IDXX | IDEXX LABORATORIES INC | 45.14 | 41.38B | ||
| RMD | RESMED INC | 28.41 | 37.82B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.51 | 34.78B | ||
| DXCM | DEXCOM INC | 50.84 | 32.89B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.38 | 23.69B |
Related stock screener links
About EKSO
Company Profile
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Company Info
EKSO BIONICS HOLDINGS INC
101 Glacier Point, Suite A
San Rafael California CALIFORNIA 94804 US
CEO: Jack Peurach
Employees: 64
Phone: 15109841761
EKSO BIONICS HOLDINGS INC / EKSO FAQ
What is the stock price of EKSO BIONICS HOLDINGS INC today?
The current stock price of EKSO is 3.8 USD. The price increased by 1.88% in the last trading session.
What is the ticker symbol for EKSO BIONICS HOLDINGS INC stock?
The exchange symbol of EKSO BIONICS HOLDINGS INC is EKSO and it is listed on the Nasdaq exchange.
On which exchange is EKSO stock listed?
EKSO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EKSO BIONICS HOLDINGS INC stock?
8 analysts have analysed EKSO and the average price target is 38.25 USD. This implies a price increase of 906.58% is expected in the next year compared to the current price of 3.8. Check the EKSO BIONICS HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EKSO BIONICS HOLDINGS INC worth?
EKSO BIONICS HOLDINGS INC (EKSO) has a market capitalization of 8.93M USD. This makes EKSO a Nano Cap stock.
How many employees does EKSO BIONICS HOLDINGS INC have?
EKSO BIONICS HOLDINGS INC (EKSO) currently has 64 employees.
What are the support and resistance levels for EKSO BIONICS HOLDINGS INC (EKSO) stock?
EKSO BIONICS HOLDINGS INC (EKSO) has a support level at 3.34 and a resistance level at 3.81. Check the full technical report for a detailed analysis of EKSO support and resistance levels.
Is EKSO BIONICS HOLDINGS INC (EKSO) expected to grow?
The Revenue of EKSO BIONICS HOLDINGS INC (EKSO) is expected to decline by -1.46% in the next year. Check the estimates tab for more information on the EKSO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EKSO BIONICS HOLDINGS INC (EKSO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EKSO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EKSO, evaluating the profitability, health, valuation and growth aspects
- EKSO BIONICS HOLDINGS INC (EKSO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EKSO BIONICS HOLDINGS INC (EKSO) Sales and EPS estimates to see what analysts future expectations are.
- EKSO BIONICS HOLDINGS INC (EKSO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EKSO BIONICS HOLDINGS INC (EKSO) Insider and Institutional Ownership to learn about the owners and their transactions.
- EKSO BIONICS HOLDINGS INC (EKSO) Stock Chart to make your own analysis
- EKSO BIONICS HOLDINGS INC (EKSO) Latest news and press-releases to stay up to date.
Does EKSO BIONICS HOLDINGS INC (EKSO) stock pay dividends?
EKSO does not pay a dividend.
When does EKSO BIONICS HOLDINGS INC (EKSO) report earnings?
EKSO BIONICS HOLDINGS INC (EKSO) will report earnings on 2025-07-28, after the market close.
What is the Price/Earnings (PE) ratio of EKSO BIONICS HOLDINGS INC (EKSO)?
EKSO BIONICS HOLDINGS INC (EKSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.35).
EKSO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EKSO. When comparing the yearly performance of all stocks, EKSO is a bad performer in the overall market: 98.28% of all stocks are doing better.
EKSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EKSO. Both the profitability and financial health of EKSO have multiple concerns.
EKSO Financial Highlights
Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -7.35. The EPS increased by 49.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.52% | ||
| ROE | -85.03% | ||
| Debt/Equity | 0.28 |
EKSO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EKSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 35.58% and a revenue growth -1.46% for EKSO